i-Seq Biotechnology
Business Services · Alabama, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
775 N University Blvd Ste 150, Mobile, A...Website
www.i-seq.comRevenue
<$5 MillionIndustry
About i-Seq Biotechnology
Is i-Seq Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if i-Seq Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at i-Seq Biotechnology
Earning: See what the market has to say on i-Seq Biotechnology recently announced quarterly report
i-Seq Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if i-Seq Biotechnology is spiking on competitors!
Funding: Get notified immidiatlly once i-Seq Biotechnology has new funding data
Product Launch: Get notified when i-Seq Biotechnology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if i-Seq Biotechnology had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
i-Seq Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
i-Seq Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about i-Seq Biotechnology.
i-Seq Biotechnology Tech Stack
A closer look at the technologies used by i-Seq Biotechnology
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding i-Seq Biotechnology
i-Seq Biotechnology, Inc. specializes in the development of novel, broad-spectrum vaccines and therapeutics targeted at infectious disease pathogens affecting human health globally. Established in 2024, the company addresses the limitations of currently available vaccines and the challenges posed by antibiotic resistance. Utilizing CRISPR interfere... Read More